Two codeine-containing products are experiencing shortages due to increased demand in the wake of the codeine upschedule

Sanofi has seen a shortage of two of its codeine products, Panamax Co and Prodeine 24, due to an “unexpected increase in demand” following the withdrawal of other codeine-containing products on the market.

“Panamax Co is currently out of stock due to increased demand,” a Sanofi spokesperson confirmed to AJP.

“A number of wholesalers received a delivery of Prodeine 24 earlier this week.

“We expect to deliver both products to wholesalers again by the end of April,” said the spokesperson.

The TGA lists a resolution date of 1 May.

“The stock challenges for these two products coincide with a number of environmental factors including the withdrawal from sale of other codeine products,” said the Sanofi spokesperson.

“We are continuing to work closely with our pharmacy and wholesale customers to meet ongoing demand.”

Sanofi currently supplies nine Schedule 4 products which contain codeine in Australia, and the remaining seven of these are in full supply.

See more about medicines shortages at the Medicine Shortages Information Initiative.